Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone in Refractory Restless Legs Syndrome
NCT06631300Phase 2Not yet recruiting
- Sponsor
- Scripps Health
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial in restless legs syndrome (RLS) comparing Prednisone group with Placebo group (2 arms). Primary endpoints: International Restless Legs Syndrome Study Group rating scale at Day 21 and Clinical Global Impression at Day 21. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
prednisone
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT06631300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631300.